Tuesday, 12 March 2013

Teriflunomide market update

Web release: Growing Uptake of Genzyme's Aubagio at Three Months Post-Launch Is Likely Driven by Perceived Product Convenience Even As Neurologists Search to Identify Appropriate Candidates, According to a Recent BioTrends Report.


Other posts in relation to Teriflunomide:

13 Sep 2012
Background:The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), .
25 Sep 2012
Is teriflunomide overpriced? I was at a meeting yesterday with some American colleagues and nearly fell off my chair when I heard that teriflunomide has been priced at $45,000 per year for American MSers. Even more ...
15 Sep 2012
Background:The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), .
13 Sep 2012
"For those of you who want more information I have uploaded Teriflunomide's highlights of prescribing information for you to review and download. I am expecting a lot of questions." CoI: multiple. Check out other afternoon ...

26 Jun 2012
Background:The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), ...
07 Jun 2012
Press release: TOWER Study (Teriflunomide). Top-line results from the TOWER trial that assessed the efficacy and safety of once-daily, oral teriflunomide in MSers with relapsing forms of MS have just been released.
09 Feb 2012
Background: Teriflunomide, an oral disease-modifying therapy in development for patients with relapsing forms of multiple sclerosis (RMS), was well tolerated and effective in reducing magnetic resonance imaging (MRI) ...
06 Jun 2012
METHODS: A total of 118 MSers with RMS were randomly assigned 1:1:1 to receive oral placebo or teriflunomide, 7 or 14 mg, once daily for 24 weeks; 86 MSers entered the 24-week extension. The primary objective was to ...

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.